Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a presentation scheduled at the Sachs 9 Annual Neuroscience Innovation Forum [1][2]. Group 1: Company Overview - Reviva is engaged in discovering, developing, and commercializing next-generation therapeutics targeting diseases that pose significant burdens to society and patients [2]. - The company's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2]. - Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]. Group 2: Presentation Details - The corporate presentation will be held on January 11, 2026, at 1:20 PM PT [2]. - The presentation will take place at the Marines' Memorial Club in San Francisco, CA [2]. - Laxminarayan Bhat, Ph.D., the Founder, President, and CEO of Reviva, will be the presenter [1][2].